Friday, April 26, 2024 4/26/2024

Development of tolerogenic dendritic cell-based immunotherapies and restorative insulin approaches to alleviate type 1 diabetes

Award Number: SC1GM127207
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

SUMMARY Type 1 diabetes (T1D) is characterized by an inability to achieve normoglycemia due to autoimmune events mistakenly targeting destruction of insulin-producing beta-cells of the pancreas. The major challenge of T1D is the two-fold onslaught whereby (1) chronic autoimmunity destroys beta-cells and (2) recovery is irreversibly lost due to the repeated chronic autoreactive attacks. Although current treatments do temperately reduce hyperglycemia, they can inadvertently lead to significant health complications (i.e. global immunosuppressive drugs impair natural host immunity and deregulate physiological functions and allogenic transplants are met with acute/chronic rejection). The long-term goals of the laboratory are to directly address these challenges of effectively alleviating T1D by developing antigen-specific tolerance to restrain autoimmune-mediated events coupled with insulin restorative strategies to alleviate hyperglycemia. The investigations have two principal aims to tackle this challenge: (1) engineering MHC class II-modified tolerogenic dendritic cell immunotherapies to specifically restrain autoreactive attacks in the beta-cell compartment without impairing natural host immunity (to pathogens or transformed cells), and (2) development of donor-derived MHC class I-matched beta-cells seeded in novel biomaterials to restore insulin production and normalize blood glucose levels. For the first aim, studies will reprogram DC towards tolerogenic states by knocking out key genes responsible for governing immunity. The approach is combined with silencing of endogenous MHC class II and replacing that with a transgene encoding a modified MHC class II that exclusively presents beta-cell autoantigen peptides with high affinity. Results will lead to tolerogenic DC solely presenting MHC class II-restricted beta-cell autoantigens upon adoptive transfer in vivo, leading to restrained autoreactive T cell responses without impairing normal host adaptive immunity. Even with success in stopping repeated autoreactive T cell attacks, tissue damage is often irreversible in mid- and late-stages of T1D. To address this challenge, the second aim will develop a restorative approach using donor-derived MHC class I-matched beta-cells seeded on novel biomaterials to restore insulin production in vivo. Donor-derived beta-cells will be genetically reprogrammed to express MHC class I matched to the recipient's haplotype; the approach will highlight the value in use of donor tissues for restorative applications. These insulin-producing donor-derived MHC class I-matched beta-cells will then be seeded in a novel patented biomaterial prior to implantation in the non-obese diabetic mouse model. Success of the approach will restrain diabetes progression by restoring normoglycemia through glucose- dependent insulin production. Findings generated from these studies will support development of innovative and novel translational and clinical-relevant therapeutic applications for combating T1D.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = -$277,559 )
2023	2021	HOWARD UNIVERSITY	2400 6TH ST NW	WASHINGTON	DC	20059	DISTRICT OF COLUMBIA	USA	Biomedical Research and Research Training	000	4	10/28/2022	NON-COMPETING CONTINUATION	-$277,559
														Subtotal = -$277,559

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2021	HOWARD UNIVERSITY (INC)	2400 6TH ST NW	WASHINGTON	DC	20059	DISTRICT OF COLUMBIA	USA	Biomedical Research and Research Training	000	4	4/15/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $377,500 )
2021	2021	HOWARD UNIVERSITY (INC)	2400 6TH ST NW	WASHINGTON	DC	20059	DISTRICT OF COLUMBIA	USA	Biomedical Research and Research Training	000	4	6/22/2021	NON-COMPETING CONTINUATION	$377,500
														Subtotal = $377,500

Issue Date FY: 2020 ( Subtotal = $377,500 )
2020	2020	HOWARD UNIVERSITY (INC)	2400 6TH ST NW	WASHINGTON	DC	20059	DISTRICT OF COLUMBIA	USA	Biomedical Research and Research Training	000	3	6/11/2020	NON-COMPETING CONTINUATION	$377,500
														Subtotal = $377,500

Issue Date FY: 2019 ( Subtotal = $377,500 )
2019	2019	HOWARD UNIVERSITY (INC)	2400 6TH ST NW	WASHINGTON	DC	20059	DISTRICT OF COLUMBIA	USA	Biomedical Research and Research Training	000	2	6/6/2019	NON-COMPETING CONTINUATION	$377,500
														Subtotal = $377,500

Issue Date FY: 2018 ( Subtotal = $361,945 )
2018	2018	HOWARD UNIVERSITY (THE)	2400 6TH ST NW	WASHINGTON	DC	20059	DISTRICT OF COLUMBIA	USA	Biomedical Research and Research Training	000	1	6/13/2018	NEW	$361,945
														Subtotal = $361,945

Grand Total All Awards = $1,216,886

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of tolerogenic dendritic cell-based immunotherapies and restorative insulin approaches to alleviate type 1 diabetes

Award Number: SC1GM127207

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer